Bo Ahrén

Senior Professor
More filtering options
  1. 2019
  2. DPP-4 inhibition and the path to clinical proof

    Bo Ahrén, 2019 Jun 19, In : Frontiers in Endocrinology. 10, JUN, 376.

    Research output: Contribution to journalArticle

  3. Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).

    Ahmadi, S., Karin Filipsson, Dimenäs, H., Isaksson, S., Imberg, H., Sjöberg, S., Bo Ahrén, Dahlqvist, S., Gustafsson, T., Tuomilehto, J., Hirsch, I. & Lind, M., 2019, In : Obesity Science Practice. 5, 2, p. 130-140

    Research output: Contribution to journalArticle

  4. 2018
  5. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Bo Ahrén, Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G. & Leiter, L. A., 2018 Sep 1, In : Diabetes, Obesity and Metabolism. 20, 9, p. 2210-2219 10 p.

    Research output: Contribution to journalArticle

  6. Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)

    Dahlqvist, S., Ahlén, E., Karin Filipsson, Gustafsson, T., Hirsch, I. B., Tuomilehto, J., Imberg, H., Bo Ahrén, Attvall, S. & Lind, M., 2018 Feb 1, In : BMJ Open Diabetes Research and Care. 6, 1, e000464.

    Research output: Contribution to journalArticle

  7. DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes

    Bugliani, M., Syed, F., Paula, F. M. M., Omar, B. A., Suleiman, M., Mossuto, S., Grano, F., Cardarelli, F., Boggi, U., Vistoli, F., Filipponi, F., De Simone, P., Marselli, L., De Tata, V., Bo Ahren, Eizirik, D. L. & Marchetti, P., 2018, In : Molecular and Cellular Endocrinology. 473, p. 186-193

    Research output: Contribution to journalArticle

  8. 2017
  9. High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes

    Jakubowicz, D., Wainstein, J., Landau, Z., Bo Ahren, Barnea, M., Bar-Dayan, Y. & Froy, O., 2017 Nov 1, In : Journal of Nutritional Biochemistry. 49, p. 1-7 7 p.

    Research output: Contribution to journalArticle

  10. Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes: A randomized clinical trial

    Jakubowicz, D., Wainstein, J., Landau, Z., Raz, I., Bo Ahren, Chapnik, N., Ganz, T., Menaged, M., Barnea, M., Bar-Dayan, Y. & Froy, O., 2017 Nov 1, In : Diabetes Care. 40, 11, p. 1573-1579 7 p.

    Research output: Contribution to journalArticle

  11. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy

    Home, P. D., Bo Ahrén, Reusch, J. E. B., Rendell, M., Weissman, P. N., Cirkel, D. T., Miller, D., Ambery, P., Carr, M. C. & Nauck, M. A., 2017 Sep 1, In : Diabetes Research and Clinical Practice. 131, p. 49-60 12 p.

    Research output: Contribution to journalArticle

  12. Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice

    Song, G., Pacini, G., Bo Ahrén & D'Argenio, D. Z., 2017 Feb 1, In : Peptides. 88, p. 74-79 6 p.

    Research output: Contribution to journalArticle

  13. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials

    Bo Ahrén, Carr, M. C., Murphy, K., Perkins, C., Rendell, M., Mallory, J., Wilson, T. & Johnson, S. L., 2017, In : Diabetes Research and Clinical Practice. 126, p. 230-239 10 p.

    Research output: Contribution to journalArticle

  14. Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring

    Bergenstal, R. M., Strock, E., Mazze, R., Powers, M. A., Monk, A. M., Richter, S., Souhami, E. & Bo Ahrén, 2017, In : Diabetes/Metabolism Research and Reviews. 33, 4, e2879.

    Research output: Contribution to journalArticle

  15. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

    Yabe, D., Eto, T., Shiramoto, M., Irie, S., Murotani, K., Seino, Y., Kuwata, H., Kurose, T., Seino, S., Bo Ahrén & Seino, Y., 2017, In : Diabetes, Obesity and Metabolism. 19, 3, p. 442-447

    Research output: Contribution to journalArticle

  16. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks

    Leiter, L. A., Gross, J. L., Chow, F. C. C., Miller, D., Johnson, S. L. & Bo Ahrén, 2017, In : Journal of Diabetes and its Complications. 31, 8, p. 1283-1285

    Research output: Contribution to journalArticle

  17. 2016
  18. Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation

    Færch, K., Vistisen, D., Pacini, G., Torekov, S. S., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Jørgensen, M. E., Bo Ahrén & Holst, J. J., 2016 Nov 1, In : Diabetes. 65, 11, p. 3473-3481 9 p.

    Research output: Contribution to journalArticle

  19. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial

    Bo Ahren, Hirsch, I. B., Pieber, T. R., Mathieu, C., Gomez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J. & Buse, J. B., 2016 Oct 1, In : Diabetes Care. 39, 10, p. 1693-1701 9 p.

    Research output: Contribution to journalArticle

  20. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

    Yabe, D., Ambos, A., Cariou, B., Duvnjak, L., Evans, M., González-Gálvez, G., Lin, J., Nikonova, E. V., de Pablos-Velasco, P., Yale, J. F. & Bo Ahrén, 2016 Oct, In : Journal of Diabetes and its Complications. 30, 7, p. 1385–1392

    Research output: Contribution to journalArticle

  21. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis

    Bo Ahrén, Galstyan, G., Gautier, J. F., Giorgino, F., Gomez-Peralta, F., Krebs, M., Nikonova, E., Stager, W. & Vargas-Uricoechea, H., 2016 Sep 1, In : Diabetes Therapy. 7, 3, p. 583-590 8 p.

    Research output: Contribution to journalArticle

  22. CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion

    Abels, M., Riva, M., Bennet, H., Ahlqvist, E., Dyachok, O., Nagaraj, V., Shcherbina, L., Fred, R. G., Poon, W., Sörhede-Winzell, M., Fadista, J., Lindqvist, A., Kask, L., Sathanoori, R., Dekker-Nitert, M., Kuhar, M. J., Ahrén, B., Wollheim, C. B., Hansson, O., Tengholm, A. & 5 othersMalin Fex, Erik Renström, Leif Groop, Valeriya Lyssenko & Nils Wierup, 2016 Jun 23, In : Diabetologia. 59, 9, p. 1928–1937 10 p.

    Research output: Contribution to journalArticle

  23. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice

    Linda Ahlkvist, Omar, B., Pacini, G. & Bo Ahrén, 2016 Jun, In : European Journal of Pharmacology. 780, p. 46–52

    Research output: Contribution to journalArticle

  24. Incretin hormone receptors are required for normal beta cell development and function in female mice

    Omar, B., Linda Ahlkvist, Yamada, Y., Seino, Y. & Bo Ahrén, 2016 May, In : Peptides. 79, p. 58-65 8 p.

    Research output: Contribution to journalArticle

  25. Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.

    Linda Ahlkvist, Omar, B., Valeur, A., Fosgerau, K. & Bo Ahrén, 2016, In : Journal of Endocrinology. 228, p. 171-178

    Research output: Contribution to journalArticle

  26. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

    Zinman, B., Bo Ahrén, Neubacher, D., Patel, S., Woerle, H-J. & Johansen, O. E., 2016, In : Canadian Journal of Diabetes. 40, 1, p. 50-57

    Research output: Contribution to journalArticle

  27. Evidence for time dependent variation of glucagon secretion in mice.

    Malmgren, S. & Bo Ahrén, 2016, In : Peptides. 76, p. 102-107

    Research output: Contribution to journalArticle

  28. Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition

    Omar, B. A. & Bo Ahrén, 2016, In : Cardiovascular Endocrinology. 5, 3, p. 82-85 4 p.

    Research output: Contribution to journalReview article

  29. Mixed meal diminishes glucose excursion compared to glucose by several adaptive mechanisms in man.

    Alsalim, W., Tura, A., Pacini, G., Omar, B., Bizzotto, R., Mari, A. & Bo Ahrén, 2016, In : Diabetes, Obesity and Metabolism. 18, 1, p. 24-33

    Research output: Contribution to journalArticle

  30. 2015
  31. Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

    Bo Ahrén, 2015, In : Diabetologia. 58, 8, p. 1740-1744

    Research output: Contribution to journalDebate/Note/Editorial

  32. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.

    Malmgren, S. & Bo Ahrén, 2015, In : Diabetologia. 58, 5, p. 1091-1099

    Research output: Contribution to journalArticle

  33. Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial.

    Jakubowicz, D., Wainstein, J., Bo Ahrén, Landau, Z., Bar-Dayan, Y. & Froy, O., 2015, In : Diabetes Care. 38, 10, p. 1820-1826

    Research output: Contribution to journalArticle

  34. Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes.

    Andersen, B., Omar, B., Rakipovski, G., Raun, K. & Bo Ahrén, 2015, In : European Journal of Pharmacology. 764, p. 189-194

    Research output: Contribution to journalArticle

  35. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.

    Ku, E. J., Jung, K. Y., Kim, Y. J., Kim, K. M., Moon, J. H., Choi, S. H., Cho, Y. M., Park, K. S., Jang, H. C., Lim, S. & Bo Ahrén, 2015, In : PLoS ONE. 10, 6, e0129477.

    Research output: Contribution to journalArticle

  36. Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice.

    Pacini, G. & Bo Ahrén, 2015, In : Peptides. 71, Jun 26, p. 66-71

    Research output: Contribution to journalArticle

  37. Glucagon-early breakthroughs and recent discoveries.

    Bo Ahrén, 2015, In : Peptides. 67, p. 74-81

    Research output: Contribution to journalReview article

  38. Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes.

    Bo Ahrén, 2015, In : Diabetes. 64, 3, p. 715-717

    Research output: Contribution to journalDebate/Note/Editorial

Previous 1 2 3 4 5 6 7 8 Next